Literature DB >> 18580205

Gracilis muscle interposition for the treatment of rectourethral, rectovaginal, and pouch-vaginal fistulas: results in 53 patients.

Steven D Wexner1, Dan E Ruiz, Jill Genua, Juan J Nogueras, Eric G Weiss, Oded Zmora.   

Abstract

BACKGROUND: The aim of this study was to review our experience with gracilis muscle interposition for complex perineal fistulas.
MATERIAL AND METHODS: A retrospective review of all patients who underwent repair of perineal fistula using the gracilis muscle between 1995 and 2007 was undertaken. Patients were divided into 2 groups according to the fistula type by gender: females (rectovaginal and pouch-vaginal) and males (rectourethral).
RESULTS: Gracilis interposition was performed in 53 patients. Seventeen women underwent 19 gracilis interpositions for 15 rectovaginal and 2 pouch-vaginal fistulas; 76% had a mean of (1-4) (mean of 2) prior failed attempt at repair. Eight patients experienced at least one postoperative complication. Two women required a second gracilis interposition. Thirty-three percent of the Crohn's disease-associated fistulas successfully healed; 75% without Crohn's successfully healed.Thirty-six males underwent gracilis interposition for rectourethral fistulas, mainly due to prostate cancer treatment; 13 (36%) had a mean of 1.5 (range 1-3) failed prior repairs. Seventeen patients experienced postoperative complications. The initial success rate in men with rectourethral fistulas was 78%. After successful second procedures in 8 patients, the overall clinical healing rate was 97%.
CONCLUSION: The gracilis muscle transposition is a safe and effective method of treating complex perianal fistulas.

Entities:  

Mesh:

Year:  2008        PMID: 18580205     DOI: 10.1097/SLA.0b013e31817d077d

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  38 in total

1.  Graciloplasty for rectourethral, rectovaginal and rectovesical fistulas: technique overview, pitfalls and complications.

Authors:  D Ruiz; B Bashankaev; J Speranza; S D Wexner
Journal:  Tech Coloproctol       Date:  2008-08-05       Impact factor: 3.781

2.  Atypical indications for transanal endoscopic microsurgery to avoid major surgery.

Authors:  X Serra-Aracil; L Mora-Lopez; M Alcantara-Moral; C Corredera-Cantarin; C Gomez-Diaz; S Navarro-Soto
Journal:  Tech Coloproctol       Date:  2013-06-28       Impact factor: 3.781

3.  Urinary incontinence and pneumaturia: management and treatment.

Authors:  Daniel Caruso; Angelo E Gousse
Journal:  Curr Urol Rep       Date:  2009-09       Impact factor: 3.092

4.  Clinical outcome and quality of life after gracilis muscle transposition for fistula closure over a 10-year period.

Authors:  M Grott; A Rickert; S Hetjens; P Kienle
Journal:  Int J Colorectal Dis       Date:  2021-01-02       Impact factor: 2.571

5.  Robotic-assisted laparoscopic segmental resection with rectoanal anastomosis: a new approach for the management of complicated rectourethral fistula.

Authors:  K H Lee; M R Lee; A Pigazzi
Journal:  Tech Coloproctol       Date:  2012-10-31       Impact factor: 3.781

Review 6.  Rectovaginal Fistulae.

Authors:  Bidhan Das; Michael Snyder
Journal:  Clin Colon Rectal Surg       Date:  2016-03

7.  Transperineal approach to complex rectourinary fistulae.

Authors:  Henry Tran; Ryan Flannigan; Daniel Rapoport
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

Review 8.  Operative considerations for rectovaginal fistulas.

Authors:  Kevin R Kniery; Eric K Johnson; Scott R Steele
Journal:  World J Gastrointest Surg       Date:  2015-08-27

9.  [Perianal fistulas in Crohn's disease: treatment results at an interdisciplinary unit].

Authors:  I Iesalnieks; H Glass; A Kilger; C Ott; F Klebl; A Agha; H J Schlitt; U Strauch
Journal:  Chirurg       Date:  2009-06       Impact factor: 0.955

10.  Transperineal management for postoperative and radiation rectourethral fistulas.

Authors:  Bryan B Voelzke; Jack W McAninch; Benjamin N Breyer; Allison S Glass; Julio Garcia-Aguilar
Journal:  J Urol       Date:  2012-09-23       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.